- Daniel Doheny, .et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis, Oncogene, 2020, Oct;39(42):6589-6605 PMID: 32929154
- Rasmus Siersbek, .et al. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis, Cancer cell, 2020, Jul 6;S1535-6108(20)30311-1 PMID: 32679107
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
- Kagoya Y, .et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2., Blood., 2014, Nov 6;124(19):2996-3006 PMID: 25217696
Biological Activity
INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
In vitro (25°C) | DMSO | 59 mg/mL (192.57 mM) | |
Water | Insoluble | ||
Ethanol | 59 mg/mL (192.57 mM) | ||
In vivo | 2% DMSO+30% PEG 300+ddH2O | 4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 32.64 mL | 163.19 mL | 326.37 mL |
0.5 mM | 6.53 mL | 32.64 mL | 65.27 mL |
1 mM | 3.26 mL | 16.32 mL | 32.64 mL |
5 mM | 0.65 mL | 3.26 mL | 6.53 mL |
*The above data is based on the productmolecular weight 306.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Catalog Num | A11041 |
---|---|
Actions | Inhibitor |
CAS No. | 941678-49-5 |
Formula | C17H18N6 |
M. Wt | 306.4 |
Purity | >98% |
Synonyms | Ruxolitinib, INCB18424 |
SMILES | C1CCC(C1)[[email protected]@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
WHI-P 154
WHI-P 154 is a JAK3 inhibitor with IC50 = 1.8uM. WHI-P 154 also Inhibits STAT1 activation, iNOS expression and NO production in macrophages…
AC220 (Quizartinib)
AC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respective…
FLLL32
FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of
TG-101348 (Fedratinib, SAR302503)
TG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic acti…
PP2
PP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays…
ZM 39923 HCl
ZM 39923 HCl is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent…
SGI-1776 (free base)
SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay, 50- and 10-fold selective versus Pim…
Go 6976
Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent…
Keywords:buy INCB018424 (Ruxolitinib) | INCB018424 (Ruxolitinib) Supplier | purchase | cost | manufacturer | order | distributor | buy 941678-49-5 | 941678-49-5 Supplier | purchase 941678-49-5 | 941678-49-5 cost | 941678-49-5 manufacturer | order 941678-49-5 | 941678-49-5 distributor